Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.
Yahoo Finance9d
Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon
AGOURA HILLS, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC). Oncotelic Therapeutics Inc., a leader in RNA-based therapeutics ...
Targeted Oncology6h
FDA OKs Trial of Novel CAR T-Cell Therapy in T-ALL/LBL
The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...
Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial
Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
Hosted on MSN8d
Eli Lilly will build 4 new manufacturing sites to increase domestic drug production
Lilly has said the company expects to increase production for its blockbuster weight loss and diabetes drugs at the 9,000 ...
Business Wire10d
LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
FDA clears LTZ's IND application to initiate trial of its myeloid engager immunotherapy to treat relapsed or refractory non-Hodgkin lymphoma.
Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon
Enabling Rapid Growth: Medicilon’s integrated platform for drug discovery, pharmaceutical research, and preclinical development will expedite the regulatory pathways for Oncotelic’s and SAPU’s ...
Leiomyosarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Promising Leiomyosarcoma Therapies such as Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, ...